David Wood, MD
Otolaryngology · Hyannis, MANPI 1053300467
Payments from drug & device makers
Across 88 payments — averaging $27.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$596
- Regeneron Healthcare Solutions, Inc.$389
- GSK$355
- Medtronic$267
- Optinose US, Inc.$152
- Stryker$101
- plus $579 from 17 others
What the payments were for
- Food & beverage$2,438100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 18 | $596 |
| Regeneron Healthcare Solutions, Inc. | 13 | $389 |
| GSK | 15 | $355 |
| Medtronic(2 entities) | 6 | $267 |
| Optinose US, Inc. | 6 | $152 |
| Stryker | 3 | $101 |
| Alk-abello, Inc | 4 | $84 |
| Novartis | 3 | $70 |
| AstraZeneca | 2 | $51 |
| Merck | 3 | $48 |
| Amgen | 2 | $42 |
| Integra Lifesciences Corporation | 1 | $40 |
| Acclarent, Inc | 2 | $35 |
| Hologic Sales And Service, LLC | 1 | $32 |
| Olympus America Inc. | 1 | $31 |
| Harmony Biosciences LLC | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Pfizer | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Kaleo, Inc. | 1 | $14 |
| Intersect ENT, Inc. | 1 | $12 |
How this compares
$2,438 in reported general payments places this provider in the 70th percentile of 298 otolaryngology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium Bromide | 61 | $1,576 |
| Omeprazole | 57 | $1,039 |
| Mometasone Furoate | 20 | $992 |
| Famotidine | 51 | $967 |
| Fluticasone Propionate | 62 | $710 |
| Azelastine Hcl | 31 | $641 |
| Montelukast Sodium | 23 | $520 |
| Pantoprazole Sodium | 18 | $403 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $179 |
| Prednisone | 25 | $68 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Hyannis
- Bruce GordonHyannis$6K
- Allan GoldsteinBoston$962K
- Michael PlattBoston$753K
- Avner AliphasNewton$735K
- Christopher BrookBoston$734K
- Gregory RandolphBoston$550K
- Ayesha KhalidConcord$511K
- Aiden ShearerBoston$444K
- Dennis PoeBoston$264K
- Phillip HuyettBoston$163K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.